Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction

Minimally invasive restorative total mesorectal excision (TME) conventionally requires an abdominal incision for specimen removal that limits its ability to reduce postoperative pain and would infection occurrence. Wound-related complications, including infections and incisional hernia, are well-recognized postoperative morbidities after minimally invasive colorectal surgery- with reported rates up to 20%- and the mini-laparotomy is often the primary site of infections and postoperative pain in colorectal surgery. Avoiding the abdominal wall extraction site may improve short-term outcomes and help reduce the cost associated with wound complications. As a result, there has been growing interest in natural orifice specimen extraction (NOSE), which eliminates the need for an extraction incision for specimen retrieval. Initially employed primarily for benign conditions, both transvaginal and transanal approaches have gradually expanded their utility to include colorectal cancer surgery without compromising bacteriological safety and oncological outcomes.

The introduction of the transanal techniques for rectal transection and single stapling anastomosis (TTSS) has enabled a more standardized application of NOSE in low rectal cancer surgery, where a complete TME and a low stapled colorectal anastomosis is required.

This study aims to compare short-term outcomes of low rectal cancer patients undergoing minimally invasive restorative TME with NOSE combined with single-stapling (SS) technique and conventional abdominal extraction incision and double-stapled anastomosis.

The primary objective of this study is to compare the postoperative outcomes of NOSE combined with SS anastomosis (NOSE) versus conventional abdominal extraction combined either with SS or double-stapled anastomosis (control), using a binary logistic regression-based Propensity Score Matched (PSM) approach.

Inclusion criteria

• Adult patients aged more than 18 years old at the time of surgery
• Patients with a histological diagnosis of rectal adenocarcinoma
• Patients who underwent surgery between January 2017 and January 2023
• Patients with a low rectal tumor meeting the Low Rectal Cancer Development Programme (LOREC) criteria

Exclusion criteria

• Patients who underwent non-restorative procedures (including abdominoperineal resection or Hartmann's procedures).
• Patients who underwent immediate or delayed coloanal anastomosis.
• Patients who underwent open surgery.
• Patients who underwent unplanned conversion from minimally invasive to open approach.
• Patients with a concomitant diagnosis of Inflammatory Bowel Disease (IBD).